LABORATORIO REIG JOFRE S.A. (ES:RJF)
BME:RJF
Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.37
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€222.15M
Enterprise Value€308.42M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)50.4
Beta0.31
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.11
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Business Model: Branded Products + CDMOHaving both branded pharmaceutical sales and contract development/manufacturing (CDMO) provides structural revenue diversification. CDMO contracts tend to be multi-year and volume-driven, supporting steadier backbook revenue and higher-margin specialty work that cushions branded-market cyclicality over several months to years.
Historically Stable Margins And Revenue Growth Pre-2025A multi-year track record of revenue expansion and double-digit EBITDA margins through 2024 indicates underlying operational competitiveness and pricing/mix advantages. This historical stability suggests the company can restore margins if demand normalizes or if higher-value CDMO work is re-weighted into sales.
Moderate Historical Leverage And Positive ROEA historically moderate debt profile and growing equity base support financial resilience, access to liquidity, and capacity to fund operations or selective investments. Positive albeit modest ROE shows the business has delivered shareholder returns historically, aiding capital stability over medium term.
Bears Say
2025 Revenue And Margin CollapseA sudden 20% revenue drop and collapse to single-digit operating margins in 2025 signals structural demand, pricing, or cost issues that materially weaken cash generation and reinvestment capacity. Such a severe setback can take multiple quarters to reverse and pressures long-term competitiveness and supplier/customer relationships.
Severely Weakened Cash Generation And FCFA swing to near-zero operating cash flow and deeply negative free cash flow increases refinancing and liquidity risk, limiting ability to fund capex, pay dividends, or invest in growth. Persistent cash volatility reduces strategic flexibility and raises likelihood of cost cutting or external funding needs.
Rising Leverage Amid Earnings VolatilityHigher leverage in 2025 combined with large EPS deterioration heightens financial risk: debt servicing will consume more cash when profits are depressed, constraining capital allocation and increasing vulnerability to interest or refinancing shocks over the medium term.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.37 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €222.15M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is in 51 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on May 07, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.087%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Options Prices
Currently, No data available
---